Key points from article :
Aqtual, a Hayward, California-based precision medicine company, secures £16 million funding "cell-free DNA platform."
Aqtual's innovative platform analyses cell-free DNA fragments to delve into protein regulation, epigenetics, and transcriptomics.
Company's CEO, highlights the platform's ability to amplify clinically relevant information in cell-free DNA, advancing disease understanding and diagnostic development.
The platform explores previously unexplored cell-free DNA fragments, with potential applications in various clinical areas, including rheumatoid arthritis.
Aqtual initiates a clinical trial for rheumatoid arthritis, aiming to predict the most effective drug classes for individual patients, potentially reducing costly drug trials.
